UroToday International Journal connects global clinicians from the urology community to one of the most extensive online urological disease collections. We focus on fast-tracked information, providing original studies and case reports within months of acceptance so our urologic community can stay up-to-date on emerging evidence that supports clinical practice decisions towards improving patient outcomes.

We provide patient education, CME programs, clinical trial recruitment services, and various articles from around the globe to our over 30,000 subscribers via the computer or mobile device, making our content both current and accessible. On top of our content provided by professional urologists from all over the globe, our editorial board is comprised of leaders in urology across the globe.

For our authors, we provide open access and do not charge for the submission process, editorial review, and publication in UIJ. It is our goal to provide positive support to our authors, as well as an efficient platform to publish their case studies, reviews, and original research.

Editorial Board

1. Tamir Aboushwareb, Wake Forest University, USA
2. Neena Agarwala, University of Nebraska Medical Center, USA
3. Ilker Akyol, GATA Haydarpasa Teaching Hospital, Turkey
4. Amir Arsanjani, New York Medical College, USA
5. Ricarda Bauer, Ludwig Maximilian University-Munich, Germany
6. Wassim Bazzi, University of California-San Diego, USA
7. Erin Bird, Scott and White Healthcare; Texas A&M University, USA
8. Tommaso Cai, University of Florence, Italy
9. John Calleary, North Manchester General Hospital, United Kingdom
10. Francisco Blasco Casares, Hospital Municipal Badalona, Spain
11. David Chen, Fox Chase Cancer Center, USA
12. Steve Chung, Northwestern University, USA
13. Simone Crivellaro, Universitaria di Udine, Italy
14. Francisco Cruz, Hospital S Joao and Faculty of Medicine, Portugal
15. Roger Dmochowski, Vanderbilt University, USA
16. Marcus Drake, Bristol Urological Institute, United Kingdom
17. Daniel Eberli, University Hospital - Zurich, Switzerland
18. Pamela Ellsworth, Warren Alpert School of Medicine, Brown University, USA
19. Christopher Evans, University of California-Davis, USA
20. Siavash Falahatkar, Guilan University of Medical Science, Islamic Republic of Iran
21. Christian Gratzke, Ludwig Maximilian University-Munich, Germany
22. Amr Hawary, Manchester Royal Infirmary, United Kingdom
23. Stefan Hinz, Charité Universitätsmedizin Berlin, Germany
24. Yasuhiko Igawa, University of Tokyo, Japan
25. Christian Ilie, University of Medicine and Pharmacy, Romania
26. William Jaffe, Pennsylvania Presbyterian Medical Center, University of Pennsylvania, USA
27. Mohamed Labib, University Teaching Hospital, Zambia
28. Thomas Sean Lendvay, Seattle Children's Hospital, University of Washington, USA
29. Richard Levin, Urodocs PA, USA
30. Jia-Wen (Kevin) Lu, E-Da Hospital, I-Shou University, Taiwan
31. Joseph Macaluso, Louisiana State University Medical School, USA
32. Maxwell Meng, University of California-San Francisco, USA
33. Walter Merkle, German Diagnostic Clinic, Germany
34. Grannum Sant, Genzyme Corp, USA
35. Walter Strohmaier, Klinikum Coburg, Germany
36. Edward Uchio, VA Connecticut Healthcare System, Yale University School of Medicine, USA
37. J. Stuart Wolf, University of Michigan, USA

Our Peer Review Process

The editor in chief assigns papers considered for publication to the associate editor who communicates with the author and expert reviewers. A statistician analyzes any statistics included. Other experts may be invited to comment where appropriate. Similar procedures may be used for other contributions to the journal. All manuscripts are subject to copy editing and formatting to conform to UIJ standards.

If a manuscript is sent for revision to an author, whether major or minor, the revised manuscript must be returned within 30 days. If it is not received at the editorial office within this timeframe, it is treated as a new submission and sent out for review to different reviewers.

24th Int'l. Prostate Cancer Update

February 19 - 22, 2014

Cascade Conference Center
Vail, Colorado USA

Society of Urodynamics, Female Pelvic Medicine
and Urogenital Reconstruction (SUFU) Winter Meeting

February 25 - March 1, 2014

Doral Golf Resort and Spa
Miami, Florida USA

78th Annual Meeting of the
Southeastern Section of the AUA
March 20 - 23, 2014

Hollywood, FL USA

29th Annual European Association
of Urology (EAU) Congress
April 11 - 15, 2014

Stockholm, Sweden

American Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

American Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA

American Urogynecologic Society (AUGS) and
the International Urogynecological Association (IUGA)
Joint Scientific Meetings

July 22 - 26, 2014

Washington, DC USA

32nd World Congress of Endourology & SWL

September 3 - 7, 2014

Taipei, Taiwan

2014 Winter Meeting of the Society of Urologic Oncology (SUO)

"Defining Excellence in Urologic Oncology"

December 3 - 5, 2014
Bethesda, MD USA

#SUO14 - Session Highlights: Nerve sparing and template choice

#SUO14 - Session Highlights: Choice of templates for low-stage testis cancer

#SUO14 - Session Highlights: Minimizing morbidity of RPLND

#SUO14 - Session Highlights: The role of SETD2 mutations in the biology of renal cell carcinoma

#SUO14 - Session Highlights: Therapy of kidney cancer: Where are we going next?

#SUO14 - Session Highlights: Impact of systemic therapy on characterization of peripheral circulating tumor cells in metastatic renal cell carcinoma

#SUO14 - Session Highlights: Accelerated growth rate of multifocal tumors after initial radiofrequency ablation

#SUO14 - Session Highlights: FSH and the metabolic syndrome

#SUO14 - Session Highlights: Non-genomic AR pathway

#SUO14 - Session Highlights: What is the impact of ECOG 3805 (CHAARTED) results on clinical practice?

#SUO14 - Session Highlights: Sequencing prior to chemotherapy

#SUO14 - Session Highlights: Cystectomy enhanced recovery pathway: Reduction in length of stay without increased morbidity or readmission

#SUO14 - Session Highlights: Declining rate of prostate biopsy in the Veterans Health Administration in the past decade: An alternate approach to limiting overdiagnosis and overtreatment of prostate cancer?

#SUO14 - Session Highlights: Role of 18-FDG PET/CT in staging of penile/urethral squamous cell carcinoma

#SUO14 - Session Highlights: Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis

#SUO14 - Abstract and Poster: Decline in the use of radiation for stage I seminoma: Analysis of the National Cancer Database

#SUO14 - Abstract and Poster: Receipt of inguinal lymph node dissection in patients with T2 penile cancer: Results from the National Cancer Database

#SUO14 - Session Highlights: Next generation sequencing of DNA from urine detects multiple bladder tumor-derived alterations and additional changes that suggest tumor heterogeneity

#SUO14 - Session Highlights: Is a 12-core biopsy of any value in patients with a previous negative prostate biopsy and visible lesion on magnetic resonance imaging?

#SUO14 - Session Highlights: Histology vs. genomics: Does Gleason 3 have the hallmarks of cancer?

#SUO14 - Session Highlights: Should MR be the standard of care before biopsy?

#SUO14 - Session Highlights: Imaging for biochemical recurrence

#SUO14 - Session Highlights: Long-term adverse effects in testicular cancer survivors

#SUO14 - Session Highlights: What a urologist should do based upon long-term side effects of chemotherapy

#SUO14 - Session Highlights: New approaches to chemotherapy in bladder cancer

#SUO14 - Session Highlights: Management of locally advanced renal cell carcinoma and management of the adrenal gland

#SUO14 - Session Highlights: Role of lymph node dissection in advanced RCC

#SUO14 - Session Highlights: Management of IVC thrombi

#SUO14 - Session Highlights: Checkpoint targeted immunotherapy

#SUO14 - Session Highlights: The role of neoadjuvant therapy in kidney cancer patients

#SUO14 - Session Highlights: Role of surgery for nodal oligometastatic disease in men with biochemical failure

#SUO14 - Session Highlights: Role of post-op RT for pN+ after prostatectomy

#SUO14 - Session Highlights: Radical prostatectomy for oligometastatic disease

#SUO14 - Session Highlights: Targeting hormone-DNA repair crosstalk in prostate cancer: Implications for disease progression and therapeutic intervention

#SUO14 - Session Highlights: Targeting PD-1 and PD-L1 in bladder cancer 

#SUO14 - Session Highlights: Clinical trials of novel targeted agents

#SUO14 - Abstract and Poster: Neoadjuvant chemotherapy is not associated with increased risk of perioperative complications, mortality, nor readmission rates in patients undergoing radical cystectomy

#SUO14 - Abstract and Poster: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

#SUO14 - Session Highlights: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

#SUO14 - Abstract and Poster: Surgical Apgar score predicts an increased risk for death and readmission following radical cystectomy

#SUO14 - Abstract and Poster: Surgical Apgar score and nephrometry score predict increased risk for major complication and death following renal mass excision

#SUO14 - Session Highlights: New insights into bladder cancer subtyping

#SUO14 - Session Highlights: Genetic findings in invasive bladder cancer: Recent Data and clinical implications

#SUO14 - Session Highlights: Epigenetic control of bladder cancer heterogeneity by non-coding RNAs

#SUO14 - Session Highlights: Towards a molecular genetic and functional classification of renal cancer

#SUO14 - Session Highlights: Biology of bladder cancer metastasis

#SUO14 - Session Highlights: Challenges and opportunities facing tumor and therapeutic heterogeneity of kidney cancer

#SUO14 - Session Highlights: RCC tumor ontogeny – lessons from the small renal mass

#SUO14 - Session Highlights: Optimal targeting of the PD-1/PDL-1 pathway in metastatic renal cell carcinoma

Genitourinary Cancers Symposium 2015

February 26 - 28, 2015

Rosen Shingle Creek
Orlando, FL USA

 #GU15 - Androgen deprivation therapy, cardiovascular risk, and multidisciplinary management of the prostate cancer patient: A German perspective - Session Highlights

#GU15 - AR splice variant 7 (AR-V7) could be a marker for treatment selection in metastatic castrate-resistant prostate cancer

#GU15 - Novel imaging modalities boost detection of early metastatic disease in prostate cancer - Session Highlights

#GU15 - Progress and challenges in penile, urethral, and testicular cancer - Session Highlights

#GU15 - Prostate cancer in 2014- 2015: Advances and ongoing challenges in therapeutics, biomarkers, and precision medicine

#GU15 - Renal cell cancer keynote: Management of RCC: Future needs and opportunities - Session Highlights

#GU15 - Year in review: Renal cell cancer - Session Highlights

#GU15 - Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial - Session Highlights

#GU15 - Metabolic pathways - Session Highlights

#GU15 - Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma - Session Highlights

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights

#GU15 - Urothelial carcinoma keynote - Session Highlights

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights

#GU15 - A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights

#GU15 - Best of journals: mCRPC treatment - Session Highlights

#GU15 - Urothelial carcinoma: Year in review - Session Highlights

#GU15 - The biology of bladder cancer metastasis - Session Highlights

#GU15 - What is new in systemic therapy for urothelial tumors? - Session Highlights

#GU15 - Best of journals: Prostate cancer - Session Highlights

#GU15 - Best of journals - Session Highlights

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights/span>

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

#GU15 - Testosterone levels in metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights

#GU15 - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial - Session Highlights

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights

#GU15 - Prostate cancer: Year in review - Session Highlights

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

#GU15 - Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights

#GU15 - Bench to bedside: Androgen resistance - Session Highlights

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights

#GU15 - Role of local therapy - Session Highlights

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights

#GU15 - Hormonal therapy: How long is enough? - Session Highlights

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights

Bayer presents latest oncology research at ASCO GU 2015

Early evidence of increase in higher-risk prostate cancers from 2011-2013

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

Society of Urodynamics, Female Pelvic Medicine
and Urogenital Reconstruction (SUFU) Winter Meeting

February 24 - 28, 2015

JW Marriott Camelback Inn Resort & Spa
Scottsdale, AZ USA

 SUFU WM 2015 - Single center experience: Sacral neuromodulation reprogramming rates - Session Highlights

 SUFU WM 2015 - Cystoscopic yield in the evaluation of recurrent urinary tract infections - Session Highlights

 SUFU WM 2015 - Upper tract imaging abnormalities related to recurrent urinary tract infections (rUTIs) rarely found in women - Session Highlights

 SUFU WM 2015 - Initial retention after Macroplastique® (MPQ) injection may be a predictor of success - Session Highlights

 SUFU WM 2015 - The vaginal microbiome and women's health: Implications for clinical translation in prevention of UTI and vaginal infections - Session Highlights

 SUFU WM 2015 - Urological surveillance and medical complications after spinal cord injury (SCI) in the United States - Session Highlights

 SUFU WM 2015 - Medical complications and urological surveillance in the US adult spin bifida population - Session Highlights

 SUFU WM 2015 - The pattern of urologic investigations and monitoring among traumatic spinal cord injured patients - Session Highlights

 SUFU WM 2015 - Association between disability status and urinary symptoms in patients with multiple sclerosis - Session Highlights

SUFU WM 2015 - Factors impacting patient tolerability and procedure time for intravesical onabotulinumtoxin A injection - Session Highlights

SUFU WM 2015 - Consistent long-term efficacy and safety of repeat BTA injections in patients with neurogenic detrusor overactivity (NDO): Final results of up to four years treatment - Session Highlights

SUFU WM 2015 - The efficacy of onabotulinum toxin A (BTA- BOTOX®) in patients with urgency urinary incontinence who have failed sacral neuromodulation (InterStim®) - Session Highlights

SUFU WM 2015 - Onabotulinum toxin A (BTA) in patients with a history of prior radiation therapy - Session Highlights

SUFU WM 2015 - Predictors of incomplete bladder emptying requiring CIC following intradetrusor onabotulinum toxin A (BTA) - Session Highlights

SUFU WM 2015 - Trends in second line therapy use for OAB before and after approval FDA approval of onabotulinum toxin A (BTA) - Session Highlights

SUFU WM 2015 - Efficacy profile in OAB patients less than 65 and ≥ 65 years of age - Session Highlights

SUFU WM 2015 - Neuromodulation in children - Session Highlights

SUFU WM 2015 - Panel discussion: Vaginal mesh update 2015 - Session Highlights

SUFU WM 2015 - Pelvic organ prolapse/reconstruction moderated poster session - Session Highlights

SUFU WM 2015 - Neuromodulation/OAB podium - Session Highlights

SUFU WM 2015 - Neuromodulation Award winner presentation - Session Highlights

SUFU WM 2015 - Diokno-Lapides Award presentation - Session Highlights

SUFU WM 2015 - State-of-the-art lecture: Minimally invasive treatments for BPH - Session Highlights

SUFU WM 2015 - Quality, cost, and value: How do we measure what we do? - Session Highlights

SUFU WM 2015 - Subspecialty training in urology: An AUA perspective - Session Highlights

SUFU WM 2015 - Pelvic organ prolapse/reconstruction moderated podium - Session Highlights

SUFU WM 2015 - Panel discussion: Common dilemmas in neuromodulation - Session Highlights

SUFU WM 2015 - Female urology/incontinence moderated poster session - Session Highlights

SUFU WM 2015 - LUTS/voiding dysfunction/neurogenic bladder moderate poster session - Session Highlights

SUFU WM 2015 - Blaivas Lectureship: Lifetime Achievement Award Winner - Session Highlights

SUFU WM 2015 - Geriatrics Society Lecture: Assessing surgical risks in the elderly: what is ‘frailty’ and how should it impact your surgical practice? - Session Highlights

SUFU WM 2015 - Panel: Management of refractory overactive bladder: What to do when third line therapies fail - Session Highlights

SUFU WM 2015 - Update on injectables for stress urinary incontinence - Session Highlights

SUFU WM 2015 - Panel: Radiological evaluation of SUI and POP – Is it necessary? - Session Highlights

SUFU WM 2015 - Panel: Urinary tract infection update - Session Highlights

SUFU WM 2015 - Panel: Management of refractory overactive bladder: What to do when third line therapies fail - Session Highlights

SUFU WM 2015 - Why do women have prolapse? Sorting fallacies from facts - Session Highlights

SUFU WM 2015 - Panel: Bladder pain - Session Highlights

30th Annual European Association
of Urology (EAU) Congress
March 20 - 24, 2015

Madrid, Spain 

#EAU15 - Tumor anatomic complexity is a predictor of malignancy but not tumor grade in patients with small renal masses (SRMs) - Session Highlights

#EAU15 - Perioperative aspirin use associated with increased risk for bleeding complication following partial nephrectomy - Session Highlights

#EAU15 - Poster: Perioperative aspirin use associated with increased risk for bleeding complication following partial nephrectomy

#EAU15 - Diagnostic workup for asymptomatic microhematuria in patients younger than 50 years - Session Highlights

#EAU15 - Poster: Improved diagnostic urine assay to select patients for initial cystoscopy

#EAU15 - Improved diagnostic urine assay to select patients for initial cystoscopy - Session Highlights

#EAU15 - Poster: Identifying patients at high risk of perioperative death from simultaneous urological and cardiac surgery for tumors involving the inferior vena cava (IVC)

#EAU15 - Identifying patients at high risk of perioperative death from simultaneous urological and cardiac surgery for tumors involving the inferior vena cava (IVC) - Session Highlights

#EAU15 - Poster: Immediate preoperative renal artery embolization facilitating laparoscopic nephrectomy for large T2b renal tumors

#EAU15 - Immediate preoperative renal artery embolization facilitating laparoscopic nephrectomy for large T2b renal tumors - Session Highlights

#EAU15 - The role of metastasectomy: What can be achieved? - Session Highlights

#EAU15 - Is there a role for neoadjuvant/adjuvant therapy? - Session Highlights

#EAU15 - Optimal imaging for bone metastasis - Session Highlights

#EAU15 - Neoadjuvant cisplatinum-based chemotherapy does not impact perioperative morbidity in patients undergoing radical cystectomy for bladder cancer - Session Highlights

#EAU15 - Poster: Neoadjuvant dose-dense MVAC for muscle invasive bladder cancer; efficacy and safety compared to the traditional MVAC regimen

#EAU15 - Neoadjuvant dose-dense MVAC for muscle invasive bladder cancer; efficacy and safety compared to the traditional MVAC regimen - Session Highlights

#EAU15 - Poster: How long should be extended follow up after surgery for renal cancer? Retrospective analysis of a cohort of patients with more than 10 years of follow up

#EAU15 - How long should be extended follow up after surgery for renal cancer? Retrospective analysis of a cohort of patients with more than 10 years of follow up - Session Highlights

#EAU15 - Poster: Longitudinal change and risk factors of severe deterioration in renal function after radical nephrectomy

#EAU15 - Longitudinal change and risk factors of severe deterioration in renal function after radical nephrectomy - Session Highlights

#EAU15 - Poster: First national population-based register of complications after radical cystectomy – results from the Swedish cystectomy registry

#EAU15 - First national population-based register of complications after radical cystectomy – results from the Swedish cystectomy registry - Session Highlights

#EAU15 - Radical cystectomy (RC) in octogenarians: Long-term experience of two high volume institutions - Session Highlights

#EAU15 - Poster: Gleason score evaluated at the level of positive surgical margin could help to predict biochemical recurrence rate after radical prostatectomy

#EAU15 - Association of cigarette smoking and smoking cessation with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer - Session Highlights

#EAU15 - Gleason score evaluated at the level of positive surgical margin could help to predict biochemical recurrence rate after radical prostatectomy - Session Highlights

#EAU15 - The impact of preoperative hypoalbuminemia on perioperative outcomes after radical cystectomy in 1262 patients - Session Highlights

#EAU15 - “Enhanced” recovery program in patients undergoing radical cystectomy: Our experience - Session Highlights

#EAU15 - Poster: Among men with low-grade prostate cancer on prostate biopsy, the 4Kscore predicts the presence of more aggressive prostate cancer

#EAU15 - Among men with low-grade prostate cancer on prostate biopsy, the 4Kscore predicts the presence of more aggressive prostate cancer - Session Highlights

#EAU15 - Poster: TERT promoter methylation is a pan-cancer biomarker with prognostic significance in prostate cancer patients

#EAU15 - TERT promoter methylation is a pan-cancer biomarker with prognostic significance in prostate cancer patients - Session Highlights

#EAU15 - Will new AR pathways inhibitor reshape the early CRPC landscape? - Session Highlights

#EAU15 - State-of-the-Art Lecture: Why does anti-androgen therapy fail? - Session Highlights

#EAU15 - True morbidity of multimodality treatment - Session Highlights

#EAU15 - Is quality of life after surgery better than after radiotherapy? - Session Highlights

#EAU15 - Is radiotherapy really less toxic than surgery? - Session Highlights

#EAU15 - Hot Topic Lecture: Chemotherapy in hormone-sensitive patients - Session Highlights

#EAU15 - Comparison of MRI/ultrasound-fusion-biopsy to systematic prostate biopsy in prediction of tumour aggressiveness and final histopathology - Session Highlights

#EAU15 - The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy - Session Highlights

#EAU15 - Poster: Prognostic significance of sarcopenia in metastatic renal cell carcinoma: Its association with survival benefit from cytoreductive nephrectomy

#EAU15 - Prognostic significance of sarcopenia in metastatic renal cell carcinoma: Its association with survival benefit from cytoreductive nephrectomy - Session Highlights

#EAU15 - Poster: Targeted prophylaxis using rectal swabs before transrectal biopsy reduces infectious complications and cost of care

#EAU15 - Targeted prophylaxis using rectal swabs before transrectal biopsy reduces infectious complications and cost of care - Session Highlights

#EAU15 - Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma - Session Highlights

#EAU15 - Family history as a risk factor for prostate cancer in a contemporary screening trial–results of the Swiss ERSPC (Aarau) - Session Highlights

#EAU15 - Phase 3 randomized trial of intravenous mannitol versus placebo prior to renal ischemia during partial nephrectomy: Impact on renal functional outcomes - Session Highlights

 #EAU15 - Poster: Nephron-sparing surgery protects from chronic kidney disease relative to radical nephrectomy but does not impact on other-causes mortality: Long-term (more than 10 years) survival and functional outcomes in patients with a T1a-T1b renal mass

#EAU15 - Nephron-sparing surgery protects from chronic kidney disease relative to radical nephrectomy but does not impact on other-causes mortality: Long-term (more than 10 years) survival and functional outcomes in patients with a T1a-T1b renal mass - Session Highlights

#EAU15 - State-of-the-Art Lecture: What would Charles Darwin make of renal cell carcinoma? - Session Highlights

#EAU15 - Is robotic cystectomy (RARC) the future standard? Con position - Session Highlights

#EAU15 - Is robotic cystectomy the future standard? – Pro position - Session Highlights

 #EAU15 - Societe Internationale d’Urologie Lecture: Lymphadenectomy in upper tract urothelial tumors - Session Highlights

#EAU15 - Molecular profiling in bladder cancer: The Cancer Genome Atlas (TCGA) project - Session Highlights

#EAU15 - Extended lymph node dissection in bladder cancer - what is the evidence? - Session Highlights

#EAU15 - New results suggest combining MRI with conventional prostate surveillance may give a generally effective prostate screening system

#EAU15 - Major new study suggests younger men need to review priorities with time after surgery for high-risk prostate cancer

#EAU15 - Changes in surgery methods significantly reduces antibiotic resistance

#EAU15 - Cost of dealing with incontinence after prostate operation averages €210 per year

#EAU15 - Study shows regaining normal sexual functioning is “rare” after prostate operations

#EAU15 - Smokers at twice risk of prostate cancer recurring after surgery

#EAU15 - Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

American Urological Association (AUA)
Annual Meeting
May 15 - 19, 2015

New Orleans, Louisiana USA

American Society of Clinical Oncology (ASCO)
2015 Annual Meeting

May 29 - June 2, 2015

McCormick Place
Chicago, IL USA

Winter Meeting of the Society of Urologic Oncology (SUO)

"Defining Excellence in Urologic Oncology"

December 2 - 4, 2015
Washington, DC USA